Elusys Therapeutics

Elusys Therapeutics is a private company focused on the development of antibody therapeutics for the treatment of infectious disease.

Elusys Therapeutics is a privately-held biopharmaceutical company focused on the development of antibody-based therapies for the treatment of infectious disease. The Company has pioneered the development of a rapid injection, anti-toxin antibody, Anthim:registered:, for the prophylaxis and treatment of anthrax disease following a biowarfare attack. Anthim has consistently demonstrated significant efficacy in multiple non-clinical animal studies and has been successfully evaluated in two clinical safety trials.